S Lefere1, F Van de Velde2, L Devisscher1, M Bekaert2, S Raevens1, X Verhelst1, Y Van Nieuwenhove3, M Praet4, A Hoorens4, C Van Steenkiste1,5, H Van Vlierberghe1, B Lapauw2, A Geerts1. 1. Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium. 2. Department of Endocrinology, Ghent University Hospital, Ghent, Belgium. 3. Department of Gastrointestinal Surgery, Ghent University Hospital, Ghent, Belgium. 4. Department of Pathology, Ghent University Hospital, Ghent, Belgium. 5. Department of Gastroenterology and Hepatology, Maria Middelares Hospital, Ghent, Belgium.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is strongly associated with obesity, dyslipidemia and insulin resistance. NAFLD often presents as simple steatosis (NAFL) but can progress to non-alcoholic steatohepatitis (NASH) and fibrosis. Current non-invasive biomarkers are not tailored to identify significant (⩾F2) fibrosis, although recent guidelines recommend a stringent follow-up of this patient population. We and others have reported on the role of pathological angiogenesis in the pathogenesis of NAFLD, highlighting pro-angiogenic factors as potential diagnostic markers. OBJECTIVE: To investigate the applicability of angiogenic and endothelial dysfunction markers as non-invasive diagnostic tools for NASH or NASH-associated fibrosis in obese patients. METHODS: In a prospective cross-sectional study, male patients undergoing bariatric surgery (n=61) and control patients (n=35) were recruited. Serum protein levels and visceral adipose tissue gene expression of endothelial dysfunction and angiogenic markers were analyzed by multiplex bead-based assay and quantitative RT-PCR, respectively. For validation, we recruited a second cohort of patients undergoing bariatric surgery (n=40) and a cohort of NAFLD patients from our outpatient clinic (n=30). RESULTS: We identified serum vascular cell adhesion molecule-1 (VCAM-1) as an independent predictor for ⩾F2 fibrosis (median 14.0 vs 8.7 ng ml-1 in patients with and without significant fibrosis; P<0.0001) with an area under the receiver-operating characteristics (AUROC) curve of 0.80. The cutoff point of 13.2 ng ml-1 showed a sensitivity of 80% and specificity of 83%. In line with these results, VCAM-1 visceral adipose tissue gene expression was also elevated in patients with fibrosis (P=0.030). In the bariatric surgery and clinical validation cohorts, VCAM-1 displayed similar AUROCs of 0.89 and 0.85, respectively. CONCLUSIONS: VCAM-1 levels are able to accurately predict significant (⩾F2) fibrosis in NAFLD patients.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is strongly associated with obesity, dyslipidemia and insulin resistance. NAFLD often presents as simple steatosis (NAFL) but can progress to non-alcoholic steatohepatitis (NASH) and fibrosis. Current non-invasive biomarkers are not tailored to identify significant (⩾F2) fibrosis, although recent guidelines recommend a stringent follow-up of this patient population. We and others have reported on the role of pathological angiogenesis in the pathogenesis of NAFLD, highlighting pro-angiogenic factors as potential diagnostic markers. OBJECTIVE: To investigate the applicability of angiogenic and endothelial dysfunction markers as non-invasive diagnostic tools for NASH or NASH-associated fibrosis in obesepatients. METHODS: In a prospective cross-sectional study, male patients undergoing bariatric surgery (n=61) and control patients (n=35) were recruited. Serum protein levels and visceral adipose tissue gene expression of endothelial dysfunction and angiogenic markers were analyzed by multiplex bead-based assay and quantitative RT-PCR, respectively. For validation, we recruited a second cohort of patients undergoing bariatric surgery (n=40) and a cohort of NAFLD patients from our outpatient clinic (n=30). RESULTS: We identified serum vascular cell adhesion molecule-1 (VCAM-1) as an independent predictor for ⩾F2 fibrosis (median 14.0 vs 8.7 ng ml-1 in patients with and without significant fibrosis; P<0.0001) with an area under the receiver-operating characteristics (AUROC) curve of 0.80. The cutoff point of 13.2 ng ml-1 showed a sensitivity of 80% and specificity of 83%. In line with these results, VCAM-1 visceral adipose tissue gene expression was also elevated in patients with fibrosis (P=0.030). In the bariatric surgery and clinical validation cohorts, VCAM-1 displayed similar AUROCs of 0.89 and 0.85, respectively. CONCLUSIONS:VCAM-1 levels are able to accurately predict significant (⩾F2) fibrosis in NAFLD patients.
Authors: V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard Journal: Gastroenterology Date: 2000-06 Impact factor: 22.682
Authors: Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass Journal: Hepatology Date: 2012-07-26 Impact factor: 17.425
Authors: Hoon-Ki Sung; Kyung-Oh Doh; Joe Eun Son; Jin Gyoon Park; Yunui Bae; Soojeong Choi; Seana Mary Lunney Nelson; Rebecca Cowling; Kristina Nagy; Iacovos P Michael; Gou Young Koh; S Lee Adamson; Tony Pawson; Andras Nagy Journal: Cell Metab Date: 2013-01-08 Impact factor: 27.287
Authors: Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg Journal: Hepatology Date: 2008-02 Impact factor: 17.425
Authors: Dieter Vanderschaeghe; Leander Meuris; Tom Raes; Hendrik Grootaert; Annelies Van Hecke; Xavier Verhelst; Frederique Van de Velde; Bruno Lapauw; Hans Van Vlierberghe; Nico Callewaert Journal: Mol Cell Proteomics Date: 2018-09-06 Impact factor: 5.911
Authors: Kunimaro Furuta; Qianqian Guo; Kevin D Pavelko; Jeong-Heon Lee; Keith D Robertson; Yasuhiko Nakao; Jan Melek; Vijay H Shah; Petra Hirsova; Samar H Ibrahim Journal: J Clin Invest Date: 2021-03-15 Impact factor: 14.808
Authors: Tobias Puengel; Sander Lefere; Jana Hundertmark; Marlene Kohlhepp; Christian Penners; Frederique Van de Velde; Bruno Lapauw; Anne Hoorens; Lindsey Devisscher; Anja Geerts; Stephanie Boehm; Qihong Zhao; John Krupinski; Edgar D Charles; Bradley Zinker; Frank Tacke Journal: Int J Mol Sci Date: 2022-06-15 Impact factor: 6.208
Authors: Jarren R Oates; Melanie C McKell; Maria E Moreno-Fernandez; Michelle S M A Damen; George S Deepe; Joseph E Qualls; Senad Divanovic Journal: Front Immunol Date: 2019-12-12 Impact factor: 7.561